NanoViricides, Inc. (NNVC)
| Market Cap | 31.53M +55.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.32M |
| EPS | -0.48 |
| Shares Out | 21.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,109 |
| Open | 1.500 |
| Previous Close | 1.460 |
| Day's Range | 1.430 - 1.580 |
| 52-Week Range | 0.850 - 2.230 |
| Beta | 1.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection... [Read more]
Financial Performance
Financial StatementsNews
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026,...
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of br...
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of...
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of ...
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to ...
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot ...
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the de...
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the de...
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs th...
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs th...
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the develo...
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter e...
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs t...
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agree...
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a s...
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of N...
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), ...
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs th...
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Stev...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown stro...
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong ac...
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains...
NanoViricides, Inc. Has Filed its Annual Report
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30,...
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical st...